Researchers call for stronger measures beyond food labels to cut sugar consumption.

Aging is characterized by chronic inflammation, oxidative stress, and mitochondrial dysfunction. Glucagon‑like peptide‑1 receptor agonists (GLP‑1 RAs), developed for type 2 diabetes and obesity, may modulate the hallmarks of aging. This review summarizes mechanistic and therapeutic evidence that GLP‑1 RAs improve mitochondrial function, reduce oxidative stress, enhance autophagy, and attenuate inflammaging. Preclinical and clinical data indicate neuroprotective, cardioprotective, and metabolic benefits. GLP‑1 RAs affect all 12 hallmarks of aging, including genomic instability, telomere attrition, epigenetic alterations, loss of proteostasis, insulin resistance, and dysbiosis. Although long‑term safety requires further evaluation, GLP‑1 RAs are promising gerotherapeutics with potential to extend healthspan.

Experts have exposed a gap between the surge of menopause information available online and the quality of medical care women receive, suggesting women’s symptoms are too often minimised or dismissed by doctors.

A University of California, Riverside-led study has found that heavily used high-puff electronic cigarettes may contain higher levels of harmful chemicals than fresh e-cigarettes, raising concerns about potential health risks for users.

New results from the Phase 3 SUNRISE clinical trial show that tezepelumab significantly reduced the need for long-term oral corticosteroid use in adults with severe oral corticosteroid-dependent asthma while maintaining asthma control and improving key clinical outcomes. The findings were published in The Lancet Respiratory Medicine(Opens in a new window).